MEMORIT 10

Negara: Israel

Bahasa: Inggris

Sumber: Ministry of Health

Beli Sekarang

Unduh Selebaran informasi (PIL)
10-08-2021
Unduh Karakteristik produk (SPC)
19-09-2023

Bahan aktif:

DONEPEZIL HYDROCHLORIDE

Tersedia dari:

UNIPHARM LTD, ISRAEL

Bentuk farmasi:

TABLETS

Komposisi:

DONEPEZIL HYDROCHLORIDE 10 MG

Rute administrasi :

PER OS

Jenis Resep:

Required

Diproduksi oleh:

UNIPHARM LTD, ISRAEL

Indikasi Terapi:

Treatment of mild to moderately severe Alzheimer`s dementia.

Tanggal Otorisasi:

2018-05-29

Selebaran informasi

                                [לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט	*
[סגירה]
סגור	*
דף הבית [http://www.health.gov.il/]	*
אודות	*
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx]	*
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx]	*
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx]	*
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx]	*
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx]	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3]	*
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx]	*
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx]	*
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx]	*
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx]	*
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx]	*
יחידות המשרד	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx]	*
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx]	*
נושאים	*
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx]	*
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
MEMORIT 10
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10 mg donepezil hydrochloride.
Excipients with known effect: Each 10 mg tablet contains 80 mg of
lactose.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet
Memorit 10 are circular, biconvex, white film-coated tablet with a
breakline on one
side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Memorit tablets are indicated for the treatment of mild to moderately
severe
Alzhei
mer’s
dementia.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults/Elderly people _
Treatment is initiated at 5 mg/day (once-a-day dosing). The 5 mg/day
dose should be
maintained for at least one month in order to allow the earliest
clinical responses to treatment
to be assessed and to allow steady-state concentrations of donepezil
hydrochloride to be
achieved. Following a one-month clinical assessment of treatment at 5
mg/day, the dose of
Memorit can be increased to 10 mg/day (once-a-day dosing). The maximum
recommended
daily dose is 10 mg. Doses greater than
10 mg/day have not been studied in clinical trials.
Treatment should be initiated and supervised by a physician
experienced in the diagnosis and
treatment of Alzheimer’s dementia. Diagnosis should be made
according to accepted
guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only
be started if a
caregiver is available who will regularly monitor drug intake for the
patient. Maintenance
treatment can be continued for as long as a therapeutic benefit for
the patient exists.
Therefore, the clinical benefit of donepezil should be reassessed on a
regular basis.
Discontinuation should be considered when evidence of a therapeutic
effect is no longer
present. Individual response to donepezil cannot be predicted.
Upon discontinuation of treatment, a gradual abatement of the
beneficial effects of Memorit is
seen.
_Paediatric population _
Donepezil hydrochloride is not recommended for use in children 
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Arab 08-05-2019
Selebaran informasi Selebaran informasi Ibrani 15-09-2023

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen